Core Insights - The A-share market saw a significant increase in new account openings, reaching 2.65 million in August 2025, a year-on-year growth of 165% and a month-on-month increase of 35% [1][2] - Cumulatively, 17.21 million new accounts were opened in 2025, representing a 47.9% increase compared to the same period in 2024 [1] Monthly New Account Data - January 2025: 1.57 million new accounts opened, with a gradual increase to 3.05 million in March before a decline in April due to market fluctuations [1][2] - August 2025: 2.65 million new accounts, significantly higher than the 1 million in August 2024, indicating strong market interest [1][2] Market Performance - The A-share market experienced a strong performance in August 2025, with the Shanghai Composite Index closing at 3,857.93 points, marking a 7.97% increase for the month [4] - The Shenzhen Component Index rose by 15.32%, while the ChiNext Index surged by 24.13%, reflecting robust market sentiment [4] Supporting Factors for Market Strength - A favorable liquidity environment with low market funding costs contributed to the upward movement of equity asset valuations [5] - Positive corporate earnings reports in sectors such as biomedicine, chemicals, and semiconductors provided a solid fundamental support for the market [5] - Domestic stimulus policies aimed at technology innovation and high-end manufacturing further bolstered long-term market confidence [6] Future Market Outlook - Analysts predict that the market will maintain a trend of oscillating upward movement, driven by accumulated profit effects and continued inflow of new capital [7] - Short-term focus will be on sectors benefiting from improved supply-demand dynamics and industry profit recovery, as well as consumer sectors supported by policy measures [9] - The technology sector, particularly AI, robotics, and semiconductors, is expected to remain a key area of investment due to rapid domestic advancements [9]

今日焦点 道氏技术：香港佳纳出资3000万美元认购脑机接口公司强脑科技Pre-B轮优先股 道氏技术公告称，公司控股子公司香港佳纳与BrainFamilyInc.及其下属控股子公司签订《Pre-B轮优先股 认购协议》，使用自有资金出资3000万美元认购标的公司Pre-B轮优先股，从而获得标的公司少数股东 权益。强脑科技（Brain Family Inc.）为全球领先的脑机接口技术公司，在脑机接口领域具备稀缺的技 术壁垒和商业化能力。公司与强脑科技在"AI+材料"战略上协同。公司拟借助强脑科技在医疗康复、教 育消费和人机交互领域应用脑机接口技术的经验，进一步增强"AI+新材料"生态赋能与商业化落地能 力，同时推进公司碳材料产品在电子皮肤等关键零部件领域应用的进程。 百济神州：公司的药物产品需完成药物早期发现等多个环节，容易受到一些不确定性因素的影响 凯迪股份：机器人相关业务暂未形成收入 凯迪股份发布股票交易风险提示公告，关注到市场对公司的机器人相关业务关注度较高，公司机器人相 关业务已立项，产品仍处于开发阶段，短期内暂无法形成收入，预计不会对公司业绩造成重大影响。 经营业绩 业绩增长 长安汽车：8月销量同比增长2 ...

Group 1 - The establishment of the Honghui Yuyi Fund marks the first smart medical equipment fund in Chongqing, with a scale of 500 million yuan, where 80% of the raised funds will be invested in the healthcare sector, contributing to the high-quality development of the biopharmaceutical industry in the region [1] - The biopharmaceutical industry is a key focus within Chongqing's "33618" modern manufacturing cluster system, identified as a trillion-level key industry, essential for upgrading the manufacturing sector towards high-end and intelligent development [1][2] - The fund aims to invest in core areas such as innovative drugs, medical devices, and medical consumables, targeting high-growth and innovative potential enterprises, while also pursuing long-term stable asset appreciation [2] Group 2 - Nantou Group has established 10 strategic industry guidance funds with a total scale of 4.53 billion yuan, primarily targeting the biopharmaceutical and optoelectronic sectors, and has invested in 36 projects [2] - The healthcare sector is experiencing a dual windfall from policy support and increasing demand, driven by factors such as global population aging and rising chronic disease rates, leading to a surge in demand for innovative drugs and medical equipment [2] - Honghui Fund (HLC), the fund manager, manages nearly 30 billion yuan in dual-currency funds and has invested in over 180 companies, with a successful exit from 82 companies, including 32 through IPOs, indicating strong potential for the new fund [3]

9月1日，迈威生物科技发布公告称，其8月29日正式向港交所重新递交了H股发行并上市的申请，并于 同日在香港联交所网站刊发了申请资料。这是继今年1月首次申请后的再次尝试。 科创板融资已花光 资料显示，迈威生物成立于2017年，2022年初在上交所科创板上市。公司由唐春山、陈姗娜和刘大涛共 同创立，主营业务为治疗用生物制品的研发、生产与销售，主要产品为抗体和重组蛋白类药物。 作为一家创新型生物医药企业，随着新药研发管线持续推进，多个创新药物处于关键临床试验研究阶 段，整体研发投入仍维持在较高水平。截至今年上半年，迈威生物公司拥有14个处于临床前、临床或上 市阶段的重点品种，包括10个创新药，4个生物类似药，专注于肿瘤和年龄相关疾病，如免疫、眼科、 骨科等领域。其中，已上市品种4个，提交上市许可申请准备阶段的品种1个，处于III 期关键注册临床 阶段品种 2 个。 从上述信息可知，迈威生物需要用钱的地方并不少。虽然有四款产品君迈康、迈利舒、迈卫健及迈粒生 进入商业化阶段，但是上述药品的销售收入也无法弥补公司近年来的亏损状况。 让投资者忧心的地方在于，迈威生物的高投入并没有高产出。虽然君迈康、迈利舒、迈卫健及迈粒生已 ...

【百济神州：公司的药物产品需完成药物早期发现等多个环节 容易受到一些不确定性因素的影响】#百 济神州发布股票交易异常波动公告#称，由于生物医药行业具有研发周期长、投入大、风险高的特点， 公司的药物产品需完成药物早期发现、临床前研究、临床开发、监管审查、生产、商业化推广等多个环 节，容易受到一些不确定性因素的影响，包括但不限于公司证明其候选药物功效和安全性的能力、候选 药物的临床结果、药监部门审查流程对临床试验的启动、时间表和进展的影响、药物或新适应症上市许 可申请技术审评及审批的进展、公司上市药物及候选药物（如能获批）获得商业成功的能力、公司获得 和维护其药物和技术的知识产权的能力、公司依赖第三方进行药物开发、生产、商业化和其他服务的情 况、公司取得监管审批和商业化药品的有限经验以及公司获得进一步的营运资金以完成候选药物开发和 实现并保持盈利的能力等。因此，公司业务运营、财务状况和经营业绩可能会受到上述不确定因素以及 其他目前未能预测的因素的影响。公司未来的业务计划、实际业绩表现、财务状况或经营结果可能与公 司预期情况有重大差异。(智通财经) ...

Core Insights - The Shenzhen-Hong Kong-Guangzhou innovation cluster has topped the "Global Innovation Index 2025" ranking, marking a significant milestone for the Guangdong-Hong Kong-Macao Greater Bay Area and showcasing China's growing innovation capabilities on the global stage [1] Group 1: Ranking and Metrics - The ranking evaluates innovation concentration through three core indicators: PCT international patent applications, scientific publications, and venture capital transactions, with the latter being a new addition this year [1] - Over the past five years, the Shenzhen-Hong Kong-Guangzhou cluster had a patent application density of 2,292 per million people, a scientific publication density of 3,775 per million, and a venture capital transaction density of 135 per million [1] - The cluster accounted for 9% of global patent applications and 2.4% of global scientific publications, ranking second and third globally, respectively [1] Group 2: Factors Contributing to Success - The new ranking method incorporates venture capital data, reflecting entrepreneurial activities and innovation financing, which has positively impacted the cluster's overall score [2] - The balanced development across inventors, scientific authors, and venture capital activities indicates strong vitality within the Shenzhen-Hong Kong-Guangzhou cluster [2] - The Greater Bay Area's technological innovation strength is attributed to continuous accumulation and collaboration among its cities, with each city contributing unique strengths [3] Group 3: Financial Support and Infrastructure - The financial support, including venture capital, is crucial for transforming favorable conditions into technological innovation capabilities [4] - By the end of 2024, Shenzhen had over 1,560 venture capital firms managing more than 1.5 trillion yuan, with 90% of funds directed towards technological innovation [4] - The combination of strong industrial foundations and supportive policies creates an ideal innovation chain from basic research to international markets [4] Group 4: Challenges and Future Directions - Despite the achievements, the Greater Bay Area faces challenges, such as insufficient investment in basic research and systemic barriers in collaboration between cities [5] - The innovation intensity ranking for the Shenzhen-Hong Kong-Guangzhou cluster is 45th globally, indicating a need to enhance per capita innovation metrics [5] - Continuous improvement and addressing weaknesses are essential for maintaining competitiveness in technological innovation [5]

2025.09.02 从行业分布来看，社保基金此次新进和增持的个股主要集中在生物医药、计算机、电子等热门赛道，也 恰恰是国家战略支持的重点方向，也是经济转型升级的关键领域。这一投资动向引起了市场广泛关注。 作为具备长期稳定盈利能力的社保基金，其每一步调仓都蕴含着深层的战略思考。那么，社保基金大幅 增持科技股背后，究竟有着怎样的逻辑？ 偏爱医药、计算机 社保基金素以"稳健"著称，其投资风格一向谨慎，注重价值投资和长期回报。近年来，这一稳健投资者 加大了对科技创新企业的布局力度。 截至二季度末，社保基金持有77家科创板上市公司股票，主要集中在电子、生物医药、机械设备、计算 机四大行业，分别有20家、13家、10家、11家公司。 持股数量方面，社保基金持股达到且超过1000万股的共有7只，持有传音控股（688036.SH）3826.4万 股，位居第一，其次为西部超导（688122.SH），为2058.1万股；持有珠海冠宇（688772.SH）、铁建重 工（688425.SH）、中科星图（688568.SH）、三一重能（688349.SH）、聚合材料（688503.SH）的股 份数量也超过1000万股。 从社保基金的 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-045 上海君实生物医药科技股份有限公司 第四届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海君实生物医药科技股份有限公司（以下简称"公司"）第四届监事会第 九次会议于2025年9月2日以通讯的方式召开。本次会议由监事会主席匡洪燕女士 主持，会议应到监事3人，实到监事3人。会议的召集和召开程序符合《中华人民 共和国公司法》（以下简称"《公司法》"）和《上海君实生物医药科技股份有 限公司章程》（以下简称"《公司章程》"）的规定，会议形成的决议合法、有 效。 二、监事会会议审议情况 （一）审议通过《关于 <公司2025年a股股票期权激励计划 草案="草案"> 及其摘 要及建议向一名董事兼主要股东授予A股股票期权的议案》 经审核，公司监事会认为《公司2025年A股股票期权激励计划（草案）》及 其摘要的内容符合《公司法》 《中华人民共和国证券法》 （以下简称"《证券法》"）、 《上市公司股权激励管理办法》 （ ...

Core Insights - The Shenzhen-Hong Kong-Guangzhou innovation cluster has topped the "Global Innovation Index 2025" ranking, marking a significant milestone for the Guangdong-Hong Kong-Macau Greater Bay Area and showcasing China's growing innovation capabilities on the global stage [1][2] Group 1: Innovation Metrics - The ranking evaluates innovation concentration through three core indicators: PCT international patent applications, scientific paper publications, and venture capital transaction volume, with the latter being a new addition this year [1][2] - Over the past five years, the Shenzhen-Hong Kong-Guangzhou cluster has achieved a patent application density of 2,292 per million people, a scientific paper publication density of 3,775 per million, and a venture capital transaction density of 135 per million [1] - The cluster accounts for 9% of global patent applications and 2.4% of global scientific paper publications, ranking second and third globally, respectively [1] Group 2: Factors Contributing to Success - The rise to the top position is attributed to the adjustment of evaluation metrics and the continuous strengthening of technological innovation within the Greater Bay Area [2] - The inclusion of venture capital data in the ranking reflects entrepreneurial activities and innovation financing, highlighting the balanced development of inventors, scientific authors, and venture capital activities in the cluster [2] - The Greater Bay Area benefits from a rich talent pool, with numerous universities and research institutions fostering high-quality local talent and attracting international expertise [3] Group 3: Financial Support and Infrastructure - Financial support, including venture capital, plays a crucial role in transforming favorable conditions into technological innovation strength, with over 1,560 venture capital firms in Shenzhen managing more than 1.5 trillion yuan, 90% of which is directed towards technological innovation [4] - The Guangdong province has seen an increase of 830.55 billion yuan in patent and trademark pledge financing during the "14th Five-Year Plan" period, benefiting 16,700 enterprises [4] - The combination of basic research, application development, industrial incubation, and international market access forms an ideal innovation chain that underpins the rise of technological innovation in the Greater Bay Area [4] Group 4: Challenges and Future Directions - Despite the achievements, the Greater Bay Area faces challenges, including insufficient investment in basic research and systemic barriers to collaboration between cities, particularly between Hong Kong, Macau, and mainland China [5] - The innovation intensity ranking for the Shenzhen-Hong Kong-Guangzhou cluster is 45th globally, indicating a need to enhance per capita innovation metrics [5] - To maintain competitiveness, the Greater Bay Area must focus on improving population quality, increasing research density, and fostering a knowledge-based economy for high-quality development [5]

智通财经APP讯，诺唯赞(688105.SH)发布公告，因自身资金需求，公司股东国寿成达拟通过大宗交易 及集中竞价的方式减持公司股份合计不超过1193.2万股，即不超过公司总股本的3%，自减持计划公告 披露之日起15个交易日后的3个月内进行。 ...